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Editorial on the Research Topic
Intestinal Homeostasis and Disease: A Complex Partnership Between Immune Cells,
Non-Immune Cells, and the Microbiome
INTRODUCTION
Epithelial cells, stromal cells, immune cells, and microbiota are fundamental components of the
intestine, and all are importantin maintaining a healthy gut (1).
Risk factors that predispose an individual to loss of gut homeostasis include genetic variants
and mutations, dysbiosis, immune dysregulation, and alterations in epithelial barrier function
(2, 3). It is still unclear how these factors interrelate and lead to the development of inflammatory
bowel diseases (IBD) in some individuals. Crohn’s disease (CD) and ulcerative colitis (UC)
are the most common types of IBD, affecting 1 in 250 individuals in the West. They are
characterized by a relapsing and remitting progression of gut inflammation, which, if not treated
with immune-suppression, leads to resection of inflamed tissue (4, 5).
The primary function of the gastrointestinal tract is to absorb nutrients and fluids to maintain
health. Infectious agents take advantage of ingested food andwater to either colonize the gut surface
(e.g., Vibrio cholera) or invade the tissues (e.g., Salmonella typhi). The vulnerability of the gut is
exacerbated by the fact that, in order to absorb nutrients, it is covered in a single layer of epithelial
cells ∼30µm thick. The epithelial layer is protected by mucus from goblet cells, especially in the
colon, and Paneth cells, which secrete anti-microbial peptides and lysozyme.
In this special issue of Frontiers in Immunology, we have collected original works and reviews
that provide new insights into the role of intestinal homeostasis and disease, with an emphasis on
immune and non-immune cells and the microbiome.
A FOCUS ON EPITHELIAL CELLS AND FIBROBLASTS IN THE
GUT
Curciarello et al. discuss the role of non-immune cells, such as epithelial cells and fibroblasts, in
intestinal homeostasis and inflammation in the context of IBD. Epithelial cells are well-equipped
to recognize infectious agents. They express Nod1 and Nod2 to recognize gram-positive and gram-
negative infectious bacteria in the cytosol as well as TLRs on their apical and basolateral surfaces
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and in endosomes. Epithelial cells also express retinoic acid-
inducible gene I to recognize RNA viruses. Additionally, they
secrete cytokines that influence underlying cellular function, such
as TGF-beta 1 and TSLP (6).
The fibroblasts that underlie the epithelium and that make
up the stroma of the lamina propria maintain the structure
of the lamina propria and make the matrix in which T cells,
plasma cells, macrophages, and dendritic cells are embedded.
In disease, however, when activated by pro-inflammatory
cytokines, fibroblasts produce large amounts of interstitial
collagenase and stromelysin, which degrade interstitial collagen
and proteoglycans, respectively, leading to loss of epithelium and
ulceration (7).
In the review by Wosen et al., emphasis is placed on
how epithelial cells in the small intestine and lung mucosa
constitutively express MHC class II. MHC II is not expressed in
healthy colonic epithelium but is induced by pro-inflammatory
cytokines in IBD. In diseases such as celiac disease, where there
is very little TNF-alpha produced but a marked increase in
interferon-gamma, MHC II increases on epithelial cells (it is
well-known that interferon-gamma induces MHCII on non-
professional antigen presenting cells). It is probable that antigen
presentation mediated byMHC-II on epithelial cells is important
in driving either tolerogenic or inflammatory responses.
Glal et al. show that activating transcription factor 3 (ATF3)
is a key molecule needed to maintain intestinal integrity
in health and inflammatory disease. ATF3-deficient mice die
if given DSS-colitis, due to impaired epithelial regeneration.
The authors suggest that IL-22 upregulates ATF3, leading to
STAT3 phosphorylation by inhibiting phosphatase activity (SH-
PTP2 and PTP-MEG2) and subsequent anti-microbial peptide
production and epithelial fucosylation.
A FOCUS ON INNATE IMMUNE CELLS IN
THE MUCOSA
Innate immune cells in intestinal mucosa are thought to be
key modulators of tolerance and inflammatory responses. Stagg
describes the heterogeneity of dendritic cells (DCs) in the
gut and their role in regulatory and effector T cell-mediated
responses in steady-state and inflammatory diseases. Bain and
Schridde highlight the heterogeneity, ontogeny, origin, and
inflammatory responses of intestinal macrophages. This is of
great relevance given that, in contrast to other tissues such as the
liver and brain where macrophages are yolk-sac derived and self-
renewing, in the gut, for the most part, mucosal macrophages are
bone marrow-derived.
Pantazi and Powell discuss the role of innate lymphoid
cells (ILC) in the gut. They emphasize that Group 3 ILCs,
which require RORγt for their development, are made up of
diverse subpopulations. ILC3 has an important function in
the response against pathogens, however dysregulated ILC3
activation may also promote inflammation, as implicated in IBD
and/or colorectal cancer.
ADAPTIVE IMMUNE CELL RESPONSES IN
THE MUCOSA
Cells and molecules associated with distinct effector profiles are
induced in the immune response characterizing IBD (8). The
evidence is now quite overwhelming that CD is caused by an
excessive Th1 response to gut microbes (9). Although IL-17A is
also markedly over-expressed in CD, treatment of patients with
an anti-IL-17A antibody exacerbated disease (10). For UC, the
situation is still unclear. It was proposed that it was driven by an
unusual type of NKT cell that made IL-13, but subsequent studies
have not shown elevated IL-13 in UC, and two clinical trials with
anti-IL-13 antibody in UCwere both negative (11). Prostaglandin
E2 (PGE2) production is known to play a role in intestinal
inflammation and exert both pro-inflammatory and regulatory
effects (12), but themechanisms by which it affects T cell function
during colitis are not clear. In this issue, Maseda et al. evaluate
the effect of autocrine vs. paracrine (non-lymphoid) secretion
of PGE2 in a murine model of T cell-dependent colitis. They
demonstrate that lymphocytes contribute to PGE2 production
and that microsomal prostaglandin E synthase-1 (mPGES-1,
which drives PGE2 production) deficient CD4+ T cells were
less able to induce colitis. In contrast, the authors suggest that
mPGES-1 deficiency in non-lymphoid cells impairs FoxP3+
regulatory cell development in mesenteric lymph nodes and
increases total CD4+ cell infiltration into colonic lamina propria.
Together, these data provide evidence that T cell PGE2 signaling
is required to restrain colitis.
Sorini et al. discuss the role of commensal bacteria-specific
CD4+ T cells, highlighting the factors involved in the generation
of these cells and their contribution to intestinal immune
homeostasis and disease. Actually, the microbiota has been
shown to promote pathogenic T cell expansion in IBD patients.
In addition, the authors discuss in overview the most commonly
used experimental model to study the induction of commensal
bacteria-specific CD4+ T cells in mice, including gnotobiotic
mice, soluble peptide-MHC tetramers, and TCR transgenic mice.
Coronado et al. present a novel model of diet-induced gut
inflammation in zebrafish larvae, identifying changes in immune
cell populations using a fluorescent reporter for macrophages,
neutrophils, and T cells. They found that myelocytes (young
granulocytes normally found in hematopoietic tissues) and T
cells orchestrate gut inflammation in response to dietary proteins.
Tregs have been identified as a significant immunosuppressive
population critically involved in maintaining intestinal
homeostasis (13). Butera et al. studied the frequency and
contribution of different Treg cells (CD3+CD4+Foxp3+ and
CD3+CD4+LAP+Foxp3–) to the extent of disease in UC
patients and a colitis mouse model. The authors concluded
that CD3+CD4+LAP+ Tregs are responsible for limiting the
extension of inflammatory lesions in UC.
Intraepithelial lymphocytes (IELs) play a key role in
maintaining intestinal immune homeostasis (14). Zhang et
al. describe original research on the role of Fas-associated
protein with death domain (FADD) in IEL development.
Dominant-negative FADD (FADD-DN) mutant mice have a
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selective deficiency of CD8αα+ TCRγδ+ cell IELs. Moreover,
loss of γδ+ IELs in the gut of FADD-DN mice aggravates
DSS-induced colitis, highlighting their important role in
intestinal homeostasis.
Pararasa et al. studied memory B cells in blood
and tissue samples of IBD patients and controls. The
authors show a reduction in CD27-IgD- memory B
cells in the blood of patients, while at the same time
observing an increased frequency of this cell population in
their mucosa.
THE ROLE OF MICROBIOTA AND DIETARY
COMPONENTS IN INTESTINAL
HOMEOSTASIS AND IMMUNE RESPONSE
The colon is colonized by more than 1 × 1013 bacterial
cells, mostly of the phyla firmicutes and bacteroidetes (15).
The microbiome shows major gradient differences along two
axes, namely the mucosa-to-luminal axis and the longitudinal
proximal intestine-to-distal intestine, with individuals showing
substantial variations (15, 16).
Parada Venegas et al. discuss the production of short-chain
fatty acids (SCFAs) by members of the commensal microbiota,
their impact on epithelial and immune cells belonging to the
innate and adaptive arms of the immune system, and their
potential use as part of either pre- or probiotic therapies for
attenuating gut inflammation.
Many factors have been shown to intervene with the
gut microbiome, including age, genetics, diet, and drugs
(15). The article by Siracusa et al. discusses the effect of
the western diet (high intake of lipids, cholesterol, and
salt) on the intestinal immune system, gut microbiota,
and CD4+ T-associated cell differentiation into different
effector sub-types. They suggest that a western diet increases
the risk of intestinal and extra-intestinal inflammation
and summarize the possible therapeutic effects of immune
modulation using dietary supplementation with fiber, indoles,
and vitamins.
Sugihara et al. summarize the role of different dietary
nutrients in the maintenance or perturbation of immune
intestinal homeostasis and highlight the relationship
between nutrition and gut immune responses, including
Th1/Th2/Th17/Treg cells, macrophages, and the microbiota.
EVOLUTIONARY BIOLOGY AND THE
DEVELOPMENT OF IBD AND CANCER
Interdisciplinary research can greatly assist in understanding
disease processes. Al Bakir et al. discuss the mechanisms
underlying the connections between IBD and colon cancer risk
from a mathematical/evolutionary perspective. They discuss the
great opportunity to follow cancer evolution using genomic
analyses over time of spatially separated colonic biopsies, from
pre-malignancy to carcinoma, which show the key factors in the
development of colorectal cancer (CRC). Clonal diversity and
evolution could be useful for predicting progression risk, which
will hopefully stimulate new thinking leading to novel early
diagnosis and prevention strategies for IBD-associated CRC.
PERSPECTIVES
Immune responses in lymph nodes and the spleen occur
in a controlled plasma-rich environment where the levels of
nutrients, hormones, and cytokines are strictly controlled. In
the gut, by virtue of the special needs of the tissue, immune
responses take place in an environment rich in exogenous
immunomodulating molecules. The list is long, but in this issue,
we have highlighted the role of diet, the microbiota, short-chain
fatty acids, prostaglandins, aryl hydrocarbon receptor ligands,
and vitamins. In this relatively brief series of articles, it was
not possible to capture the full breadth of activity in mucosal
immunology and inflammation in humans, but there is no doubt
that this is one of the most exciting areas of immunology, with
many surprises ahead.
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